The Reynders, McVeigh Core Equity Fund (the “Fund”) seeks capital preservation and long-term capital growth.
We employ a positive screening approach that “screens in” companies that demonstrate strength of balance sheet, integrity of management, and a commitment to act as part of a global community focused on positive change. As part of our research process, we combine financial analysis with an analysis of each company’s environmental, social and governance (“ESG”) performance. We believe that understanding a company’s ESG profile complements traditional financial analysis. In order to incorporate ESG factors into the investment discipline, we analyze a wide range of sources and incorporate that information into the overall research process. These sources include a company’s own ESG reports, comparative studies done by specialists in ESG research, and the use of an outside research service that aggregates ESG data into quantifiable measures.
DIRECTING CAPITAL TO PRODUCTIVE AND POSITIVE USERS
• Improved efficiency through medical discovery
• New technologies and efficiency in industry
• Mobility of information and access
• Health and well-being
• Fossil-fuel free
The actively-managed global fund seeks to achieve its objective by investing at least 80% of its net assets (plus borrowings for investment purposes) in equity securities. As part of its principal investment strategy, and under normal market conditions, the Fund expects to invest at least 60% of its net assets in domestic equity securities with market capitalizations of $15 billion or more, and expects to invest at least 15% of its net assets in equity securities of companies located in developed foreign markets across any market capitalization and American Depositary Receipts.
(as of 3/31/20)
*% of total assets
(as of 3/31/20)
Net Assets: $20.8M
# Equity Securities/ % of Assets: 41/ 97.41%
Median Market Cap: $37.34B
Weighted Avg. Market Cap: $151.58B
Fund Facts & Characteristics
Share Class: Institutional
Inception Date: 03/29/2019
Nasdaq Symbol: ESGEX
CUSIP Number: 14064D 733
Initial Investment: $1,000
Subsequent Investment: $100
Gross Expense Ratio*: 1.44%
Net Expense Ratio*: 0.96%
* contractual through 5/31/21
CHAIRMAN & CHIEF EXECUTIVE OFFICER
PRESIDENT & CHIEF INVESTMENT OFFICER
ERIC SHRAYER, CFA, CFP®
SENIOR VICE PRESIDENT & RESEARCH DIRECTOR
Holdings (as of 3/31/20)
|% 0F NET ASSETS||% 0F NET ASSETS|
|1. Mastercard, Inc. -A||3.79%||21. Unilever plc – Spon ADR||2.23%|
|2. Teladoc Health, Inc.||3.71%||22. MarketAxess Holdings, Inc.||2.22%|
|3. Becton, Dickinson and Co.||3.71%||23. Orsted A/S||2.20%|
|4. Abbott Laboratories||3.57%||24. Xilinx, Inc.||2.18%|
|5. Koninklijke DSM NV.||3.49%||25. Nike, Inc. -CL B||2.17%|
|6. CVS Health Corp.||3.23%||26. Tomra Systems ASA||2.10%|
|7. Rockwell Automation, Inc.||3.14%||27. PayPal Holdings, Inc.||2.07%|
|8. Analog Devices, Inc.||3.01%||28. Novo Nordisk A/S – Spon ADR||2.01%|
|9. Nvidia Corp.||2.94%||29. Halma plc||2.00%|
|10. Danaher Corp.||2.91%||30. Illumina, Inc.||1.97%|
|11. Canadian Natl Railway Co.||2.90%||31. Ormat Technologies, Inc.||1.94%|
|12. Microsoft Corp.||2.81%||32. Xylem, Inc.||1.86%|
|13. Kerry Group plc – A||2.80%||33. Amphenol Corp. -CL A||1.84%|
|14. Alphabet, Inc. -CL C||2.76%||34. Novozymes A/S – B Shares||1.79%|
|15. AptarGroup, Inc.||2.64%||35. New York Times Co.||1.73%|
|16. The Walt Disney Co.||2.58%||36. L’Oréal.||1.62%|
|17. Apple, Inc.||2.56%||37. First Republic Bank/CA||1.62%|
|18. Fiserv, Inc.||2.53%||38. Capgemini SE||1.55%|
|19. BillerudKorsnäs AB||2.31%||39. Tesla, Inc.||1.20%|
|20. Panasonic Corp. -Spon ADR||2.25%||40. Frequency Therapeutics, Inc.||1.03%|
|41. CRISPR Therapeutics AG||0.43%|
Performance (as of 3/31/20)
Total Return (%) Annualized Returns (%)
| Cumulative Returns
|MSCI World Index||-21.05||8.56||0.53||4.00||-21.05||-10.39||N/A||N/A||N/A||-10.34||-10.39|
Performance data quoted represents past performance and does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor’s shares, when redeemed, may be worth more or less than their original cost. Current performance may be lower or higher than the performance data quoted. Investors may obtain performance data current to the most recent month-end by calling 1-800-950-6868.
Top Contributors/Detractors to Performance Q1 2020
|BY SECTOR||BY HOLDINGS|
|Top Contributors||Avg Weight||Contribution||Top Contributors||Avg Weight||Contribution|
|Utilities||4.26||-0.23||Teladoc Health, Inc.||3.20||1.99|
|Real Estate||2.01||-0.56||Nvidia Corp.||2.82||0.34|
|Consumer Discretionary||5.17||-0.66||Tesla, Inc.||0.11||0.20|
|Consumer Staples||6.67||-0.68||Novo Nordisk A/S – Spon ADR||1.93||0.09|
|Materials||9.61||-1.00||Automatic Data Processing||0.44||0.08|
|Top Detractors||Avg Weight||Contribution||Top Detractors||Avg Weight||Contribution|
|Information Technology||25.08||-3.86||Envista Holdings Corp.||1.52||-1.29|
|Financials||5.10||-1.80||Amalgamated BK of New York – A||1.52||-1.02|
|Industrials||9.75||-1.76||The Walt Disney Co.||2.64||-0.99|
|Communication Services||7.62||-1.41||Rockwell Automation, Inc.||3.05||-0.79|
|Health Care||22.38||-1.14||Analog Devices, Inc.||2.91||-0.72|
Disclosure: Investors should carefully consider the investment objectives, risks, and charges and expenses of the fund before investing. The prospectus contains this and other information about the fund, and it should be read carefully before investing. Investors may obtain a copy of the prospectus by calling 1-800-950-6868 or by visiting www.reyndersmcveighfunds.com.
Investing involves risk, including loss of principal. There is a risk that because the fund’s environmental, social, and governance (ESG) criteria may exclude securities of certain issuers for nonfinancial reasons, the fund may forgo some market opportunities available to funds that do not use these criteria. Foreign investments, including ADRs, present special risks including currency fluctuation, the potential for diplomatic and political instability, regulatory and liquidity risks, foreign taxation and differences in auditing and other financial standards. Risks of foreign investing are generally intensified for investments in emerging markets.
The Fund may not achieve its objectives. Portfolio holdings may change over time.
This information does not constitute an offer to sell or a solicitation of any offer to buy securities by anyone in any jurisdiction where it would be unlawful under the laws of that jurisdiction to make such an offer or solicitation. This information is only for the intended recipient and may not be distributed to any third party.
1 All holdings information is provided for informational purposes only and should not be interpreted as a recommendation to purchase any of the securities/sectors listed. The holdings listed represent the complete list of holdings within the Reynders, McVeigh Core Equity Fund as of 3/31/2020.
Industry “Sector Breakdown” is provided from the Global Industry Classification Standard (“GICS”), developed and exclusively owned by MSCI, Inc. (“MSCI”) and Standard & Poor’s Financial Services, LLC (“S&P”). All GICS data is provided “as is” with no warranties. The Adviser may have reclassified/classified certain securities in or out of a sub-industry. Such reclassifications are not supported by MSCI or S&P.
Reynders, McVeigh Capital Management, LLC is an investment adviser registered with the U.S. Securities Exchange and Commission (“SEC”).
Distributed by Ultimus Fund Distributors, LLC
Investors should carefully consider the investment objectives, risks, and charges and expenses of the Fund before investing. The prospectus contains this and other information about the Fund, and it should be read carefully before investing. Investors may also obtain a copy of the prospectus by calling 1-800-950-6868.
Distributed by Ultimus Fund Distributors, LLC.
You are now leaving the Reynders, McVeigh Mutual Fund website and entering Reynders, McVeigh Capital Management, LLC website.
Reynders, McVeigh Core Equity Fund established December 2018.
Report to made available at later date.